TREX1 is upregulated after treatment of malignant cells with DNA damaging agents, radiation therapy, or UV light exposure, and it attenuates tumor response to chemotherapy and radiotherapy by modulating the activation of immune signaling pathways, which are induced by cytosolic DNA fragments generated by treatment-induced DNA damage [13, 15, 47–50]. Here, TREX1 is linked to neoplasm.